A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial.
Meredith K. Chuk
No relevant relationships to disclose
Brigitte C. Widemann
No relevant relationships to disclose
Charlotte H. Ahern
No relevant relationships to disclose
Joel M. Reid
No relevant relationships to disclose
AeRang Kim
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Maya Lodish
No relevant relationships to disclose
Elizabeth Fox
No relevant relationships to disclose
Brenda Weigel
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose